



### LaRDR Sites and Principal Investigators

*(Italics = ethics/governance approval pending)*  
**Alfred Hospital:** Susan Morgan  
**Auckland City Hospital (NZ):** *Leanne Berkahn*  
**Austin Health:** Eliza Hawkes  
**Ballarat Hospital:** Geoffrey Chong  
**Barwon Health:** Sumita Ratnasingam  
**Box Hill Hospital:** Denise Lee  
**Cabrini Health:** *Melita Kenealy*  
**Canberra Hospital:** Dipti Talaulikar  
**Concord Hospital:** Judith Trotman  
**Epworth Hospital:** Miles Prince  
**Fiona Stanley Hospital:** Dustin Hall  
**Flinders Medical Centre:** *Kate Manos*  
**Gold Coast University Hospital:** Tara Cochrane  
**Gosford Hospital:** Tasman Armytage  
**Liverpool Hospital:** Nicolas Viala  
**Monash Health:** Stephen Opat  
**Northern Health:** *Teresa Leung*  
**Peter MacCallum Cancer Centre:** Michael Dickinson  
**Port Macquarie Base Hospital:** Jock Simpson  
**Prince of Wales Hospital:** *Annmarie Bosco*  
**Princess Alexandra Hospital:** Colm Keane  
**Royal Adelaide Hospital:** Pratyush Giri  
**Royal Darwin Hospital:** Emma Palfreyman  
**Royal Hobart Hospital:** Anna Johnston  
**Royal North Shore Hospital:** Luke Coyle  
**Royal Perth Hospital:** *John Balendra*  
**Sir Charles Gairdner Hospital:** Chan Cheah  
**St Vincent's Hospital, Melbourne:** Matthew Ku  
**St Vincent's Hospital, Sydney:** Nada Hamad  
**Sunshine Coast University Hospital:** Manjunath Narayana  
**Toowoomba Hospital:** Howard Mutsand  
**Townsville Hospital:** Joel Wright  
**Western Health:** Duncan Carradice

### LaRDR Steering Committee

**Stephen Opat (chair):** Monash Health  
**Mary Ann Anderson:** Peter MacCallum Cancer Centre  
**Leanne Berkahn:** Auckland Hospital, NZ  
**Chan Cheah:** Sir Charles Gairdner Hospital  
**Michael Dickinson:** Peter MacCallum Cancer Centre  
**Maheer Gandhi:** Princess Alexandra Hospital  
**Pratyush Giri:** Royal Adelaide Hospital  
**Eliza Hawkes:** Austin Health  
**Anna Johnston:** Royal Hobart Hospital  
**Colm Keane:** Princess Alexandra Hospital  
**Zoe McQuilten:** Monash University  
**Stephen Mulligan:** Royal North Shore Hospital  
**Dipti Talaulikar:** Canberra Hospital  
**Judith Trotman:** Concord Hospital  
**Janne Williams:** Consumer representative  
**Erica Wood:** Monash University

### Working Groups

**Chronic Lymphocytic Leukaemia**  
**Stephen Mulligan (chair):** Royal North Shore Hospital  
**Xavier Badoux:** St George Hospital  
**Gavin Cull:** Sir Charles Gairdner Hospital  
**Bryone Kuss:** Flinders Medical Centre  
**Paula Marlon:** Princess Alexandra Hospital  
**Manjunath Narayana:** Sunshine Coast University Hospital  
**Stephen Opat:** Monash Health  
**Sumita Ratnasingam:** Geelong Hospital  
**Dipti Talaulikar:** Canberra Hospital  
**Constantine Tam:** Peter MacCallum Cancer Centre  
**Erica Wood:** Monash University

### Pathology Review

**Dipti Talaulikar (chair):** Canberra Hospital  
**Simone Birch:** Princess Alexandra Hospital  
**Christina Brown:** Royal Prince Alfred Hospital  
**David Ellis:** Clinpath Pathology  
**Yasmin Harvey:** Sullivan Nicolaides Pathology  
**Sam Hitchins:** University of Tasmania  
**Sanjiv Jain:** Canberra Hospital  
**Peter Jessup:** Royal Hobart Hospital  
**Sunder Juneja:** Peter MacCallum Cancer Centre  
**Daniel Kearney:** Royal Adelaide Hospital  
**Beena Kumar:** Monash Health  
**Stephen Lade:** Peter MacCallum Cancer Centre  
**Kenneth Lee:** University of Sydney  
**Connall Leslie:** PathWest Laboratory Medicine  
**Eileen Long:** Hobart Pathology  
**Adrienne Morey:** Canberra Hospital  
**Lakshmi Nath:** Clinpath Pathology  
**Debbie Norris:** QML Pathology  
**Andrew Parker:** St Vincent's Hospital, Sydney  
**Jeremy Parry:** Fiona Stanley Hospital

### Data Validation

**Allison Barraclough:** Fiona Stanley Hospital  
**Joshua Casan:** Monash Health  
**Tania Cushion:** Austin Health  
**Aditya Tedjaseputra:** Peter MacCallum Cancer Centre

### LaRDR Administration

**Administration:** School of Public Health and Preventive Medicine, Monash University  
**Coordinating Principal Investigator:** Stephen Opat  
**Investigators:** Erica Wood, Zoe McQuilten, Eliza Hawkes  
**Senior Research Officer:** Gayathri St George (maternity leave from August)  
**Research Officer:** Eliza Chung  
**Data Manager:** Cameron Wellard  
**Data Officer:** Fiona Chen  
**Deputy Director (Operations):** Neil Waters

Welcome to the LaRDR report for 2021! It has been 5 years since we recruited the first participant. This year was full of growth in recruitment, research and collaborations. We are excited to share this success with you as contributors and great supporters of the registry.

### MESSAGE FROM THE CHAIR – PROF STEPHEN OPAT

I am pleased to share with you LaRDR's progress in 2021. The registry had 33 participating sites and 4971 registered patients at the end of 2021. We recently welcomed sites from the Northern Territory and will be welcoming New Zealand in the near future. Current projects using registry data are outlined below. We welcome your ongoing input and research ideas.


We received encouraging feedback at the first Data Managers Meeting held in June. We hope you found the interactive session useful for data management at your site. We have made a number of enhancements to the case report forms based on your feedback. These will enhance the data quality in the registry and improve clarity of the results.

I thank the *LaRDR team at Monash University*, all the site *Principal Investigators and staff*, our *industry and community partners*, and of course our *participants*. We would not have come this far (and reached our 5<sup>th</sup> anniversary) without all of you!

### LaRDR ACTIVITIES AND PROGRESS

**Governance and management:** The registry is overseen by a multidisciplinary *Steering Committee* and managed by Ms Gayathri (Gaya) St George, Ms Eliza Chung, and the LaRDR team at Monash University's School of Public Health and Preventive Medicine. LaRDR uses an "opt-off" consent model to enable maximum participation. Participants are provided with an information brochure during clinical visits and invited to discuss their potential participation.

**Participation:** 27 sites have contributed data to LaRDR so far. The median age at diagnosis is 62.3 years (IQR 52.6-73.6), and 59% are male. CLL baseline and treatment data, captured using a CLL-specific case report form, are maturing.



The *LaRDR Pathology Review Committee* consists of haematologists and anatomical pathologists who can ensure the accurate and consistent diagnosis of cases entered into the registry. The *World Health Organization (WHO) Classification Working Group* provide support to ensure the disease classifications used in the database are up-to-date with the WHO classifications. Dr Allison Barraclough from the *Data Validation Working Group* joined the LaRDR team to attend the Data Managers meeting and provided clinical insights in the discussion of challenges in capturing lymphoma data. LaRDR provides *custom-built annual data reports* for participating sites to support benchmarking and practice improvement. We value your ongoing feedback on the reports.

### REGISTRY PROJECTS

LaRDR provides a platform for international partnerships. We support investigator-initiated studies, including young investigators, and encourage project ideas.

We were pleased to have Dr Simran Bhopal work with LaRDR on an analysis of CLL data during her *Monash MD Scholarly Intensive Placement*, co-supervised by Dr Mary Ann Anderson from Peter MacCallum Cancer Centre and the *CLL Working Group*, and A/Prof Eliza Hawkes, Austin Health and Lymphoma Lead for LaRDR at Monash SPHPM.

### International Partnerships

A/Prof Eliza Hawkes and Prof H. Miles Prince (Epworth/Peter MacCallum Cancer Centre) led LaRDR's contribution of peripheral T-cell lymphoma cases to the international *T-cell Project 2.0* collaborative project, alongside participation from Europe, United States, South America,

and Asia. This work resulted in the abstract titled [Subtypes of Mature T and NK Cell Lymphoma According to 2016 WHO Classification. Preliminary Report of The International Prospective T-Cell Project 2.0.](#)



Dr Nicole Wong Doo (Concord Hospital) oversaw the contribution of nodular lymphocyte-predominant Hodgkin lymphoma data to the [Global nLPHL One Working Group \(GLOW\) initiative](#). It collects data from the United States and other international centres to study treatment parameters and patient outcomes.

A/Prof Eliza Hawkes led the LaRDR contribution of adult Hodgkin lymphoma data to the [Hodgkin Lymphoma International Study for Individual Care \(HoLISTIC\) Consortium](#). This collaboration based in the United States aims to estimate a prediction model of early disease outcomes, transition probabilities and risk of treatment to improve outcomes in Hodgkin lymphoma.



Prof Chan Cheah and Dr Elizabeth Smyth (Sir Charles Gairdner Hospital) are co-leading a large-scale multicentre study on the [Influence of Anti-Retroviral Prophylaxis on Outcomes after R-CHOP Chemotherapy in DLBCL](#) with National University Health System in Singapore. The aim of the study is to evaluate effects of RT-inhibitor prophylaxis on patient outcomes.

### Investigator-Initiated Studies

[ICAN: Immunoglobulin use and outcomes in Chronic lymphocytic leukaemia And Non-Hodgkin lymphoma](#) is a registry-based study funded by the National Blood Authority and led by A/Prof Zoe McQuilten from Monash University. ICAN is currently collecting follow-up data on patients with CLL and NHL. The results will help to improve infection prevention and treatment for patients, and, where possible, rationalise the use of immunoglobulin therapy.



Dr Stephen Walker (St Vincent's Hospital, Melbourne) together with Dr Matthew Ku and Prof Con Tam (Peter MacCallum Cancer Centre) analysed CLL/SLL data pre- and post-Richter's transformation provided by LaRDR in a study of [factors influencing outcome in Richter's transformation](#) recently presented at the American Society of Hematology conference.

Dr Michael Shipton (Peter MacCallum Cancer Centre) is publishing the results of a [review of patterns of treatment and survival outcomes for patients with large B-cell lymphoma](#), supervised by A/Prof Michael Dickinson (Peter MacCallum Cancer Centre/The Royal Melbourne Hospital) and Dr Gareth Gregory (Monash Health). Dr Adrian Minson (Peter MacCallum Cancer Centre) is conducting a [review of the patterns of treatment and outcomes for patients with mantle cell lymphoma](#), in collaboration with the Australasian Lymphoma Alliance. LaRDR was pleased to contribute data for these analyses.

Dr James Nguyen (Eastern Health), supervised by A/Prof Eliza Hawkes, is analysing LaRDR data to describe [characteristics of Hodgkin lymphoma in Australia](#). The study aims to identify the clinical, demographic and treatment patterns of Hodgkin lymphoma patients and allow comparison with other populations. A/Prof Tara Cochrane and Dr ZhongZhen Goh (Gold Coast University Hospital) are using the registry data to analyse the [Front-line Treatment of Elderly Patients with Classical Hodgkin Lymphoma](#). It aims to evaluate the palliative and curative treatment for elderly patients and assess the outcomes. Data analyses are conducted using SafeHaven, a secure platform for sensitive data sharing, supported by the Monash secure e-research platform.

A/Prof Eliza Hawkes and Dr Shivam Agrawal (Austin Health) are recruiting for a study of [polatuzumab use in DLBCL patients](#). Dr Diva Baggio (Austin Health), supervised by Prof Stephen Opat (Monash Health) and A/Prof Eliza Hawkes, is summarising the analysis of [ibrutinib use in CLL and MCL patients](#). We thank LaRDR participating sites for their contributions to these analyses and patients enrolled in the Named Patient Programs.

### REGISTRY MEETINGS and PRESENTATIONS

Dr Diva Baggio presented at the [13th Annual International T-Cell Lymphoma Forum](#) on epidemiology and therapeutic trends of T- and NK-cell lymphomas in an Australian context. Dr Michael Shipton presented his study at [BLOOD 2021](#), along with abstracts by Dr Diva Baggio, Dr James Nguyen and a [LaRDR 5-year overview](#) on behalf of the LaRDR investigators. Dr Stephen Walker's abstract was accepted at ASH as noted above.



The [2021 ALA/LaRDR Annual Investigator Meeting](#) chaired by Prof Chan Cheah (Chair, ALA) and Prof Stephen Opat (Chair, LaRDR) was held online. The [ALA](#) aims to increase national collaborative lymphoma clinical research output and facilitate engagement with international partnerships and industry. Participants enjoyed project snapshots from Dr Simran Bhopal, Dr Diva Baggio, Dr James Nguyen, Dr Kenneth Lim (St Vincent's Hospital, Melbourne), Dr Stephen Walker, and Dr Maciej Tatarczuch (Monash Health), followed by discussion. ALA and LaRDR continue to encourage collaboration for lymphoma research across Australia.

### To contact LaRDR

Website: [www.lardr.org](http://www.lardr.org)  
Email: [sphpm-lymphoma@monash.edu](mailto:sphpm-lymphoma@monash.edu)  
Phone: 1800 811 326

### LaRDR appreciates the support from these organisations:

